stuck in a funk, page-7

Markets in the US down over night and the biotechnology sector continued to slide. Contributing to this was the news a late-stage test of Amgen's skin cancer drug disappointed researchers, and Halozyme suspending a study of its pancreatic cancer drug due to patient safety concerns.

I suspect similar events in Australian biotech with both Prima and Prana having disappointing trial results are weighing down the sector as a whole.

We need some good news to buoy the sector. I am hopeful Alchemia will provide that news when it's it's phase III results are released!